Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
Biotech
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Adam's Take
STAT+

For biotech analysts, the outlook for 2018 is dark and stormy

  • Adam Feuerstein

By Adam Feuerstein Dec. 18, 2017

Reprints
storm clouds
Drew Angerer/Getty Images

Robyn Karnauskas’s biotech blue skies have turned dark and stormy.

During the biotech boom-boom years, Citi’s large-cap biotech analyst earned a reputation for being eternally sunny. To Karnauskas, every drug was a blockbuster. Buy ratings were bountiful. Price targets moved in only one direction: up.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

‘Microdosing’ is touted by ’shroomers and Reddit users. Science…
‘Microdosing’ is touted by ’shroomers and Reddit users. Science is starting to test their claims —…
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
Dope Sick: A harrowing story of best friends, addiction…
Dope Sick: A harrowing story of best friends, addiction — and a stealth killer
European Union drug pricing proposal for the pandemic treaty…
European Union drug pricing proposal for the pandemic treaty generates pushback
Inflation caused a sizable drop in net drug prices…
Inflation caused a sizable drop in net drug prices in late 2022, analysis finds
FDA report details problems at Global Pharma plant involved…
FDA report details problems at Global Pharma plant involved in eye drop recall

Comments are closed.

Recommended Stories